Charles Bennett to Health Care Costs
This is a "connection" page, showing publications Charles Bennett has written about Health Care Costs.
Connection Strength
2.160
-
The excessive cost of early stage bladder cancer care: are providers really to blame? Cancer. 2010 Aug 01; 116(15):3530-2.
Score: 0.279
-
Evaluating the supportive care costs of severe radiochemotherapy-induced mucositis and pharyngitis : results from a Northwestern University Costs of Cancer Program pilot study with head and neck and nonsmall cell lung cancer patients who received care at a county hospital, a Veterans Administration hospital, or a comprehensive cancer care center. Cancer. 2008 Sep 15; 113(6):1446-52.
Score: 0.245
-
Cancer-associated neutropenic fever: clinical outcome and economic costs of emergency department care. Oncologist. 2007 Aug; 12(8):1019-26.
Score: 0.226
-
Cost considerations in the management of cancer in the older patient. Oncology (Williston Park). 2007 Jun; 21(7):851-7; discussion 858, 860, 862 passim.
Score: 0.224
-
Evaluating the total costs of cancer. The Northwestern University Costs of Cancer Program. Oncology (Williston Park). 2003 Jan; 17(1):109-14; discussion 119-21.
Score: 0.165
-
Evaluating the financial impact of clinical trials in oncology: results from a pilot study from the Association of American Cancer Institutes/Northwestern University clinical trials costs and charges project. J Clin Oncol. 2000 Aug; 18(15):2805-10.
Score: 0.139
-
Comparing cost-effectiveness analyses for the clinical oncology setting: the example of the Gynecologic Oncology Group 111 trial. Cancer Invest. 2000; 18(3):261-8.
Score: 0.134
-
Why Biologics and Biosimilars Remain So Expensive: Despite Two Wins for Biosimilars, the Supreme Court's Recent Rulings do not Solve Fundamental Barriers to Competition. Drugs. 2018 Nov; 78(17):1777-1781.
Score: 0.124
-
Health care economics and bone marrow transplantation. Cancer Treat Res. 1997; 77:377-99.
Score: 0.109
-
Costs of care and outcomes for high-dose therapy and autologous transplantation for lymphoid malignancies: results from the University of Nebraska 1987 through 1991. J Clin Oncol. 1995 Apr; 13(4):969-73.
Score: 0.096
-
Medical care costs of intravenous drug users with AIDS in Brooklyn. J Acquir Immune Defic Syndr (1988). 1992; 5(1):1-6.
Score: 0.077
-
Evaluating the total costs of chemotherapy-induced febrile neutropenia: results from a pilot study with community oncology cancer patients. Oncologist. 2007 Apr; 12(4):478-83.
Score: 0.055
-
Estimating the cost of cancer: results on the basis of claims data analyses for cancer patients diagnosed with seven types of cancer during 1999 to 2000. J Clin Oncol. 2004 Sep 01; 22(17):3524-30.
Score: 0.046
-
The financial burden of cancer: estimates from a study of insured women with breast cancer. J Support Oncol. 2004 May-Jun; 2(3):271-8.
Score: 0.045
-
Does reimbursement affect physician decision making? Cancer Treat Res. 2000; 102:137-49.
Score: 0.033
-
Costs of care associated with high-dose therapy and autologous transplantation for non-Hodgkin's lymphoma: results from the University of Nebraska Medical Center 1989 to 1995. Bone Marrow Transplant. 1999 Sep; 24(6):679-84.
Score: 0.033
-
Cost analysis of second-line therapies for platinum-refractory ovarian cancer: reimbursement dilemmas for Medicare patients. Cancer Invest. 1999; 17(8):559-65.
Score: 0.031
-
Cancer insurance policies in Japan and the United States. West J Med. 1998 Jan; 168(1):17-22.
Score: 0.029
-
Cost-effective models for flutamide for prostate carcinoma patients: are they helpful to policy makers? Cancer. 1996 May 01; 77(9):1854-61.
Score: 0.026
-
Performance measurement in prostate cancer care: beyond report cards. Urology. 1996 Mar; 47(3):356-65.
Score: 0.026
-
Purchasing oncology services. Kerr L. White Institute/American Cancer Society Task Force on Purchasing Oncology Services. Cancer. 2000 Jun 15; 88(12):2876-86.
Score: 0.009
-
Comparative study of the clinical efficacy of two dosing regimens of flutamide. Mol Urol. 2000; 4(3):259-63;discussion 265.
Score: 0.008